PKO Investment Management Joint Stock Co Sells 3,500 Shares of AbbVie Inc. $ABBV

PKO Investment Management Joint Stock Co cut its position in shares of AbbVie Inc. (NYSE:ABBV) by 9.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,584 shares of the company’s stock after selling 3,500 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in AbbVie were worth $8,239,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the second quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie in the second quarter worth approximately $39,000. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a voluntary agreement with the Trump administration that includes a pledge to invest $100 billion in U.S. R&D and capital over the next decade and an exemption from tariffs and future pricing mandates — a regulatory win that reduces trade/tariff uncertainty and signals long‑term U.S. investment. AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
• Positive Sentiment: AbbVie is buying a Tempe, Arizona manufacturing facility from West Pharmaceutical Services and acquiring manufacturing/supply rights for the SmartDose 3.5mL on‑body delivery system — immediate capacity and device IP that support next‑generation injectable medicines and reduce supply risks. AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
• Positive Sentiment: AbbVie inked an exclusive licensing/development deal with RemeGen for RC148, a PD‑1/VEGF bispecific antibody, in a pact worth up to roughly $4.95–$5.6 billion in milestones — a meaningful oncology pipeline add that could drive long‑term upside if clinical development succeeds. AbbVie, RemeGen partner on experimental solid tumor treatment
• Neutral Sentiment: AbbVie joined other large drugmakers calling for the FDA to modernize post‑approval change rules — could improve manufacturing flexibility long‑term but timing and regulatory outcomes are uncertain. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: AbbVie reported completion of its ABBV‑932 bipolar depression Phase 2 trial — a development milestone investors will watch for data readouts, but clinical timing/outcomes remain the next catalysts. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion: What Investors Should Watch Next
• Negative Sentiment: As part of the U.S. agreement, AbbVie agreed to provide lower Medicaid prices (via TrumpRx) for a three‑year period — this pricing concession introduces near‑term revenue/margin risk and is the main downside investors are weighing against the tariff relief and investment commitments. Abbvie, US reach agreement to cut drug prices

AbbVie Trading Down 0.0%

Shares of AbbVie stock opened at $219.99 on Tuesday. The firm has a market capitalization of $388.80 billion, a P/E ratio of 166.66, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The business’s fifty day simple moving average is $226.75 and its 200 day simple moving average is $215.76. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Evercore ISI increased their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday, November 3rd. Morgan Stanley increased their price objective on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $246.89.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.